Completed cases

Complaints considered by the Code of Practice Panel are judged on the evidence provided by both parties. Once concluded a case report is published on this website. Good compliance decisions rely on both the interpretation of the Code and an understanding of its application, published case reports help in this regard and set precedent in a particular set of circumstances. When making decisions on compliance with the Code, knowledge gained from previous case reports can be beneficial.                        

Search options for completed cases can be found below, please scroll down.

Please note that abbreviations/acronyms can only be searched under the Text search.

Where searching under clause number please look under sub clause where one exists, eg Clause 6.1 not just 6.

Click on the blue arrow below to search completed cases.  Searches can be run by free Text, Case number, Respondent, Complainant or Clause Number.

The results can then be filtered by: Year Received or Applicable Code Year. Results will be automatically ordered by 'Completed Date - Most Recent First', other options are available to select. 

The order of the results displayed can be changed by clicking in the box beside 'Order Results By'.

Please Note:

Cases can only link to clauses in the interactive 2019 or 2016 Codes.

 

 

 

Search completed cases

An anonymous, non-contactable ex-employee complained about the arrangements for a meeting, ‘Psoriasis Management of Patients Over Time – PsoMOT’, organised by Almirall Spain to which UK doctors were invited to attend. The complainant alleged that Almirall UK selected and invited UK doctors to attend the lavish meeting in Berlin on Friday, 26 October 2018 based on their prescribing of Almirall products. The meeting was attended by Almirall UK representatives and on Friday, 26 October guests flew in...

No breach Clause(s): 2, 9.1, 22.1

Applicable Code: 2019

Received: 01 May 2019

Completed: 20 August 2019

  An ex-employee of Indivior complained that in 2017 the company had not disclosed payments made to health professionals, donations or sponsorships in the UK. The detailed response from Indivior is given below. The Panel noted that the Code required companies to document and publicly disclose certain transfers of value made directly or indirectly to health professionals and healthcare organisations located in Europe; in the UK, this had to be via a central platform. The Panel noted Indivior’s submission...

Applicable Code: 2020

Received: 20 December 2018

Completed: 19 August 2019

Gilead Sciences Europe complained about the promotion of Juluca (dolutegravir/rilpivirine) by ViiV Healthcare.  Juluca was a combination of two antiretroviral (ARV) medicines used in the treatment of human immune deficiency virus type-1 (HIV-1) infection in adults who were virologicallysuppressed on a stable ARV regimen for at least 6 months.  Gilead also marketed ARV combination medicines for the treatment of HIV.  The detailed response from ViiV is given below. 1  Reduction of antiretroviral (ARV) exposure and potential associated...

Applicable Code: 2016

Received: 07 September 2018

Completed: 15 August 2019

A health professional complained that the Disclosure UK database incorrectly indicated that he/she had received financial support from Amgen. The detailed response from Amgen is given below. The Panel noted that the data disclosed on Disclosure UK for 2015 referred to the complainant who had the same first and last name as the health professional who had received the transfers of value but a different address. It appeared to the Panel, based on the information provided by Amgen,...

Applicable Code: 2016

Received: 21 December 2018

Completed: 10 August 2019

An anonymous contactable individual complained about a poster inviting pharmacists to attend a continuing professional development (CPD) meeting to look at asthma medication reviews and a minor illness referral service.  The name of a retail pharmacy group appeared at the top of the poster and the GlaxoSmithKline logo appeared at the bottom.  The complainant also drew attention to a LinkedIn post about Bexsero (meningococcal group B vaccine) from several employees of GlaxoSmithKline. The detailed response from...

Applicable Code: 2016

Received: 07 December 2018

Completed: 09 August 2019

An anonymous, non-contactable individual, who described him/herself as a concerned health professional, complained that a flyer for an International Diabetes Summit which was organised by the All Party Parliamentary Group (APPG) and held at the House of Commons in December 2018 did not have any sponsorship statement despite Novo Nordisk’s heavy involvement with the event; its chief executive officer (CEO) was one of the speakers. The complainant alleged that the meeting was advertised across many media...

Applicable Code: 2016

Received: 11 December 2018

Completed: 30 July 2019

No summary, outwith the scope of the Code

No breach Clause(s): Outwith the scope of the Code

Applicable Code: 2016

Received: 21 November 2018

Completed: 24 July 2019

A study published online in the British Medical Journal (12 September 2018) was entitled ‘Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource’ (Goldacre et al 2018). The study objectives included assessing compliance rates with the European Commission’s requirement that all trials on the EU Clinical Trials Register (EUCTR) posted results to the registry within 12 months of completion (final compliance date 21 December 2016). The study objectives...

Applicable Code: 2016

Received: 12 September 2018

Completed: 22 July 2019

A study published online in the British Medical Journal (12 September 2018) was entitled ‘Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource’ (Goldacre et al 2018). The study objectives included assessing compliance rates with the European Commission’s requirement that all trials on the EU Clinical Trials Register (EUCTR) posted results to the registry within 12 months of completion (final compliance date 21 December 2016). The study objectives...

Applicable Code: 2016

Received: 12 September 2018

Completed: 18 July 2019

An individual complained about a leaflet promoting Imbruvica (ibrutinib) on Janssen-Cilag’s exhibition stand at a meeting held in Glasgow in November 2018.  The complainant alleged that the leaflet was misleading because it used the claim ‘Destination survival’ without any mention of survival data and it misleadingly implied that there was a survival benefit with Imbruvica which was not so. Imbruvica was used in the treatment of chronic lymphocytic leukemia (CLL), relapsed or refractory mantle cell lymphoma...

Applicable Code: 2016

Received: 02 December 2018

Completed: 12 July 2019

About 1212 result(s)